Fulcrum Therapeutics Soars 12.58% on Upgrade

Fulcrum Therapeutics' stock surged 12.58% in pre-market trading on May 26, 2025, marking a significant rise for the biopharmaceutical company.

Leerink Partners has upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating. This upgrade comes as the company's shares have declined by approximately 15% over the past year. The analyst, Joseph Schwartz, cited the potential for upcoming data on the company's lead product as a key factor in the upgrade.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing new medicines by unlocking gene control mechanisms. The company's innovative approach to gene therapy has garnered attention from analysts, who see potential in its pipeline of treatments.